Recent Finacing
Recent Raise
Dynacure is a clinical-stage biotech developing DYN101, an antisense oligonucleotide targeting dynamin 2 for centronuclear and myotubular myopathies, conducting Phase 1/2 adult trials with planned pediatric expansion.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Dynacure.
